We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed at $135.87 in the latest trading session, marking a -1.29% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.24% for the day. Meanwhile, the Dow experienced a drop of 0.01%, and the technology-dominated Nasdaq saw a decrease of 0.26%.
The stock of HIV and hepatitis C drugmaker has risen by 0.31% in the past month, leading the Medical sector's loss of 0.68% and undershooting the S&P 500's gain of 6.42%.
Market participants will be closely following the financial results of Gilead Sciences in its upcoming release. The company plans to announce its earnings on May 7, 2026. The company's upcoming EPS is projected at $1.89, signifying a 4.42% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $6.89 billion, indicating a 3.41% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $8.63 per share and revenue of $30.15 billion, which would represent changes of +5.89% and +2.39%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 0.26% fall in the Zacks Consensus EPS estimate. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
From a valuation perspective, Gilead Sciences is currently exchanging hands at a Forward P/E ratio of 15.94. For comparison, its industry has an average Forward P/E of 21.88, which means Gilead Sciences is trading at a discount to the group.
We can also see that GILD currently has a PEG ratio of 1.82. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.61 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 94, finds itself in the top 39% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Gilead Sciences (GILD - Free Report) closed at $135.87 in the latest trading session, marking a -1.29% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.24% for the day. Meanwhile, the Dow experienced a drop of 0.01%, and the technology-dominated Nasdaq saw a decrease of 0.26%.
The stock of HIV and hepatitis C drugmaker has risen by 0.31% in the past month, leading the Medical sector's loss of 0.68% and undershooting the S&P 500's gain of 6.42%.
Market participants will be closely following the financial results of Gilead Sciences in its upcoming release. The company plans to announce its earnings on May 7, 2026. The company's upcoming EPS is projected at $1.89, signifying a 4.42% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $6.89 billion, indicating a 3.41% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $8.63 per share and revenue of $30.15 billion, which would represent changes of +5.89% and +2.39%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 0.26% fall in the Zacks Consensus EPS estimate. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
From a valuation perspective, Gilead Sciences is currently exchanging hands at a Forward P/E ratio of 15.94. For comparison, its industry has an average Forward P/E of 21.88, which means Gilead Sciences is trading at a discount to the group.
We can also see that GILD currently has a PEG ratio of 1.82. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.61 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 94, finds itself in the top 39% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.